[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515766":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":39,"responsibleParty":53,"collaborators":55,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":37,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":37,"overallStatus":41,"whyStopped":37,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High Dose (25mg)","EXPERIMENTAL","PEX010 (Oral Psilocybin), 25mg; single dose administered 24hrs prior to first of 5 weekly MET sessions",[13],"Drug: Psilocybin",{"label":15,"type":16,"description":17,"interventionNames":18},"Low dose (1mg)","ACTIVE_COMPARATOR","PEX010 (Oral Psilocybin), 1mg; single dose administered 24hrs prior to first of 5 weekly MET sessions",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Psilocybin","Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing",[9,15],[26,27],"magic mushrooms","PEX010",[29],{"name":30,"affiliation":5,"role":31},"Leah Mayo, PhD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Kaitlin O'Grady","CONTACT","587-893-0257",null,"pactlab@ucalgary.ca",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":37},"RECRUITING","Calgary","Alberta","T2N 4Z6","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-114.08529,51.05011,{"lat":51,"lon":50},{"type":54,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[56,58,60],{"name":57,"class":6},"Johns Hopkins University",{"name":59,"class":6},"University of Maryland",{"name":61,"class":62},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100515766","phase-2-psilocybin-assisted-psychotherapy-for-alcohol-use-disorder-100515766",false,"NCT05995769","Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder","Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial","PAP-AUD","Inclusion Criteria:\n\n* Meets DSM-5 AUD criteria of at least moderate severity\n* Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days\n* Desire to decrease alcohol consumption\n* Limited lifetime hallucinogen use\n\nExclusion Criteria:\n\n* Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months\n* Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis\n* Active suicidal ideation or serious attempt within past 3 years\n* Currently pregnant, nursing, or trying to become pregnant\n* Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test","ALL","22 Years","65 Years",{"count":75,"type":76},128,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).",[82,83],"Alcohol Use Disorder","Alcoholism","2024-05-06",{"date":86,"type":87},"2024-05-07","ACTUAL",{"date":89,"type":87},"2024-03-20",{"date":91,"type":76},"2027-10-01",{"name":5,"class":6},1]